Generic Medicine Info
Indications and Dosage
Mild dementia in Alzheimer's disease, Moderate dementia in Alzheimer's disease, Severe dementia in Alzheimer's disease
Adult: Initially, 5 mg once daily at bedtime, may increase after 1 mth to 10 mg once daily, if necessary. Max: 10 mg daily.
Elderly: Initially, 5 mg daily at bedtime, increase if necessary up to 10 mg once daily at bedtime after 4-6 wk.
May be taken with or without food. Take in the evening just prior to retiring. 23-mg tab: Swallow whole, do not split/crush/chew. ODT: Allow to dissolve on the tongue & follow w/ water.
Special Precautions
Patient w/ history of asthma or COPD, sick sinus syndrome, supraventricular conduction abnormalities, susceptibility to peptic ulcer, seizures, GI or urinary tract obstruction. Hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Diarrhoea, muscle cramps, fatigue, nausea, vomiting, headache, insomnia, abnormal dreams, common cold, aggression, agitation, anorexia, dizziness, hallucinations, pruritus, rash, syncope, urinary incontinence, bradycardia, duodenal/gastric ulcers, GI haemorrhage, seizures. Rarely, AV block, extrapyramidal symptoms, hepatitis, bladder outflow obstruction, sino-atrial block.
Potentially Fatal: Rarely, neuroleptic malignant syndrome.
Patient Counseling Information
May impair ability to drive or operate machinery.
Monitoring Parameters
Monitor mental status, wt, pulse, symptoms of GI intolerance or bleeding.
Symptoms: Cholinergic crisis characterised by severe nausea, vomiting, salivations, sweating, bradycardia, hypotension, resp depression, collapse, convulsion, muscle weakness. Management: Supportive treatment and use of anticholinergic such as IV atropine.
Drug Interactions
Increased risk of neuroleptic malignant syndrome w/ antipsychotics. Synergistic effect w/ succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists (e.g. bethanechol). May interfere w/ the activity of anticholinergic medications. Increased plasma concentration when used w/ CYP3A4 inhibitors (e.g. ketoconazole, erythromycin) and CYP 2D6 inhibitors (e.g. fluoxetine, quinidine). Decreased plasma concentrations w/ enzyme inducers (e.g. rifampicin, phenytoin).
Mechanism of Action: Donepezil reversibly and noncompetitively inhibits centrally-active acetylcholinesterase that is responsible for the hydrolysis of acetylcholine, resulting to increased concentration of acetylcholine in the CNS.
Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: 3-4 hr.
Distribution: Volume of distribution: 12-16 L/kg. Protein binding: Approx 96% (to albumin (75%) and α1-acid glycoprotein (21%).
Metabolism: Extensively metabolised in the liver, mainly by CYP3A4 isoenzyme and to a lesser extent by CYP2D6, into 4 major metabolites.
Excretion: Via urine (57%, as unchanged drug and metabolites) and faeces (15%). Elimination half-life: Approx 70 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Donepezil, CID=3152, (accessed on Jan. 21, 2020)

Store between 15-30°C.
MIMS Class
Neurodegenerative Disease Drugs
ATC Classification
N06DA02 - donepezil ; Belongs to the class of anticholinesterases. Used in the management of dementia.
Anon. Donepezil. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 09/11/2016.

Aricept Solution (Eisai Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 09/11/2016.

Buckingham R (ed). Donepezil Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. . Accessed 09/11/2016.

Donepezil Hydrochloride 5 mg and 10 mg Tablet, Film Coated (Major Pharmaceuticals). DailyMed. Source: U.S. National Library of Medicine. Accessed 09/11/2016.

Donepezil Hydrochloride Tablet, Film Coated (Camber Pharmaceuticals, Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 09/11/2016.

Joint Formulary Committee. Donepezil hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 09/11/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Donepezil Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 09/11/2016.

Disclaimer: This information is independently developed by MIMS based on Donepezil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Donezil
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in